ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
65,381.26
6.23%
S&P 500
5,298.72
0.99%
Dow Jones
39,817.67
0.66%
US Dollar vs Yen
154.994
-0.96%
Brent Oil
82.585
0.04%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Theseus Pharmaceuticals Inc (THRX)

  7. Theseus Pharmaceuticals Inc (THRX) ニュース

THRX

Theseus Pharmaceuticals (THRX)

Theseus Pharmaceuticals Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:THRX
日付受信時刻ニュースソース見出しコード企業名
2024/02/2623 : 00Edgar (US Regulatory)Form 15-12G - Securities registration termination [Section 12(g)]NASDAQ:THRXTheseus Pharmaceuticals Inc
2024/02/1614 : 15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:THRXTheseus Pharmaceuticals Inc
2024/02/1506 : 00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:THRXTheseus Pharmaceuticals Inc
2024/02/1504 : 26Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:THRXTheseus Pharmaceuticals Inc
2024/02/1504 : 24Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:THRXTheseus Pharmaceuticals Inc
2024/02/1504 : 22Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:THRXTheseus Pharmaceuticals Inc
2024/02/1500 : 44Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:THRXTheseus Pharmaceuticals Inc
2024/02/1500 : 35Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
2024/02/1422 : 30PR Newswire (US)Theseus Pharmaceuticals Announces Closing of Tender OfferNASDAQ:THRXTheseus Pharmaceuticals Inc
2024/02/1402 : 36Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
2024/02/0807 : 21Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
2024/02/0807 : 15Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
2024/01/3022 : 52Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
2024/01/3022 : 23Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
2024/01/3022 : 00Business WireConcentra Announces Calculation of Additional Price Per Share and Extension of Expiration Date for Tender Offer for Theseus PharmaceuticalsNASDAQ:THRXTheseus Pharmaceuticals Inc
2024/01/1023 : 47Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:THRXTheseus Pharmaceuticals Inc
2024/01/1022 : 51Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:THRXTheseus Pharmaceuticals Inc
2023/12/2220 : 52Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:THRXTheseus Pharmaceuticals Inc
2023/12/2220 : 36Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:THRXTheseus Pharmaceuticals Inc
2023/12/2220 : 30PR Newswire (US)Theseus Pharmaceuticals Enters into Agreement to Be Acquired by Concentra Biosciences for between $3.90 and $4.05 in Cash per Share Plus a Contingent Value RightNASDAQ:THRXTheseus Pharmaceuticals Inc
2023/12/0420 : 30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:THRXTheseus Pharmaceuticals Inc
2023/11/2720 : 37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:THRXTheseus Pharmaceuticals Inc
2023/11/2720 : 30PR Newswire (US)Theseus Pharmaceuticals Confirms Receipt of Unsolicited Expression of Interest from Foresite Capital, LLC and OrbiMed Advisors LLC and Unsolicited Proposal from Concentra Biosciences LLCNASDAQ:THRXTheseus Pharmaceuticals Inc
2023/11/2506 : 23Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:THRXTheseus Pharmaceuticals Inc
2023/11/1806 : 01Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:THRXTheseus Pharmaceuticals Inc
2023/11/1521 : 00Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:THRXTheseus Pharmaceuticals Inc
2023/11/1406 : 05PR Newswire (US)Theseus Pharmaceuticals Announces Process to Explore Strategic AlternativesNASDAQ:THRXTheseus Pharmaceuticals Inc
2023/11/0806 : 05PR Newswire (US)Theseus Pharmaceuticals to Participate in the Stifel 2023 Healthcare ConferenceNASDAQ:THRXTheseus Pharmaceuticals Inc
2023/11/0806 : 03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:THRXTheseus Pharmaceuticals Inc
2023/11/0105 : 13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:THRXTheseus Pharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:THRX

最近閲覧した銘柄

FX
USDEUR
US Dollar vs Euro
FX
USDGBP
US Dollar vs Sterling
AMEX
XLF
Financial Select Sector
FX
USDJPY
US Dollar vs Yen
NASDAQ
TSLA
Tesla
USOTC
BNPQY
BNP Paribas (QX)
NYSE
KO
Coca Cola
NASDAQ
AAPL
Apple
COIN
BTCUSD
Bitcoin
NYSE
DIS
Walt Disney
AMEX
XLV
Health Care Select Sector
NYSE
NKE
Nike
PM
XAUUSD
Gold vs US Dollar
NYSE
VZ
Verizon Communications
AMEX
XLE
Energy Select Sector SPDR
NYSE
MCD
McDonalds
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有